by nms-sync | Sep 14, 2021 | News
Entrectinib, the kinase inhibitor drug that was initially discovered and developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has received approval for marketing and reimbursement from the Italian drug agency...
by nms-sync | Feb 9, 2021 | News
Nerviano, 9 February 2021
NMS Group has been named the winner of the “Value creators’ category at the prestigious ‘China Awards 2021′ during the online event held by the Italy China Foundation on Monday 8 February 2021. The “Value...
Welcome and Check out our new motion picture!
Recent Comments